Analyst Expects Black Diamond Therapeutics Inc (NASDAQ: BDTX) To Make Big Moves

After Hours

There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Earlier, Yahoo Finance discussed this stock as it revealed Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Stocks Info

As a NASDAQ listed company, BDTX falls under the Healthcare sector while operating within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $4.34 and fluctuated between $4.4900 as its day high and $4.1000 as its day low. The current market capitalization of Black Diamond Therapeutics Inc is $224.12M. A total of 0.77 million shares were traded on the day, compared to an average of 1.60 shares.

Insider Activity

Aside from predicting where a stock will go, investors also consider insider trades as an indicator of the stock’s future direction. During the recent three months, BDTX has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 12 BUYs and 1 SELLs from insiders. Insiders purchased 5,120,832 shares during that period but sold 25,000.

In the most recent transaction, BIOTECH GROWTH N V bought 400,000 shares of BDTX for 2.34 per share on Oct 17. After the transaction, the 10% Owner now owns 8,517,839 company shares. In a previous transaction on Jul 05, Behbahani Ali bought 1,000,000 shares at 5.00 per share. BDTX shares that Director owns now total 4,448,757.

Among the insiders who bought shares, RA CAPITAL MANAGEMENT, L.P. acquired of 935,850 shares on Jul 05 at a per-share price of $5.00. This resulted in the Director holding 3,213,828 shares of BDTX after the transaction. In another insider transaction, BIOTECH GROWTH N V bought 1,000,000 shares at $5.00 per share on Jun 30. Company shares held by the 10% Owner now total 8,117,839.

In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. According to analysts who have offered 12-month price targets for BDTX in the last 3 months, the mean price target is $10.50 with high estimates of $11.00 and low estimates of $10.00. In terms of 52-week highs and lows, BDTX has a high of $6.85 and a low of $1.22.

As of this writing, BDTX has an earnings estimate of $BioNTech SE per share for the current quarter. EPS was calculated based on a consensus of USD/BDT estimates, with a high estimate of $Volatility Shares Trust 2x Bitc per share and a lower estimate of $Cidara Therapeutics, Inc..

Balance Sheet Annually/Quarterly

The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. BDTX’s latest balance sheet shows that the firm has $209.79M in Cash & Short Term Investments as of fiscal 2021. There were $28.46M in debt and $23.64M in liabilities at the time. Its Book Value Per Share was $2.60, while its Total Shareholder’s Equity was $195.90M.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BDTX is Buy with a score of 5.00.

Most Popular

Related Posts